Elevance Health: Carelon and the Internal Profit Engine of Vertical Integration
Elevance Health’s (ELV) Q2 2026 financial results, reported on July 15, 2026, provide a historic demonstration of the dual-engine economics of modern managed care. While the company's core health benefits insurance segment suffered severe margin compression due to elevated medical costs in Medicaid, its vertically integrated health services segment, Carelon, acted as a vital stabilizer, generating more than half of the company's segment operating gains.
Health Benefits Margin Compression vs. Carelon's Stability
For the three months ended June 30, 2026:
- Operating Revenue: $49.826 billion, up 0.8% year-over-year.
- Consolidated Benefit Expense Ratio (MBR): Rose to 89.7% (up 80 bps YoY), reflecting expected elevated medical cost trends in Medicaid, partially offset by stronger Individual ACA results.
- GAAP Shareholders' Net Income: $1.463 billion, down 16.1% YoY from $1.743 billion.
- Adjusted Diluted EPS: $7.45, down 15.7% from $8.84.
Segment Performance Breakdown
The divergence between ELV's insurance and services segments is dramatic:
-
Health Benefits (Insurance):
- Operating revenue rose 2.7% to $42.720 billion.
- Operating gain fell 42.6% to $896 million (down from $1.560 billion in Q2 2025).
- Operating margin compressed by 170 bps to a meager 2.1%.
- This pressure was primarily driven by Medicaid, where ELV is forecasting a negative 1.75% operating margin for FY 2026 due to post-pandemic "unwinding" acuity mismatches (healthier members leaving, leaving a sicker pool).
-
Carelon (Services and PBM):
- Operating revenue grew 6% to $19.2 billion, driven by Carelon Services risk-based solutions and CarelonRx product revenue.
- Operating gain rose 1% to $948 million ($582 million from CarelonRx, up 8.6%; $366 million from Carelon Services, down 8.5%).
- Carelon represented 51.4% of Elevance's total reportable segment operating gain ($948 million out of $1.844 billion, excluding Corporate & Other).
Strategic Retreat from Medicaid
Faced with unsustainable Medicaid margins, Elevance is executing a disciplined, state-by-state portfolio review:
- The company exited the Washington, D.C. Medicaid market effective August 1, 2026 (a contract covering 250,000 enrollees valued at $8.8 billion over five years).
- CEO Gail Boudreaux confirmed that Elevance "expect[s] to exit additional Medicaid markets over the next 12 to 18 months where we do not see a path to sustainable performance."
CMS Risk Adjustment Settlement
In Corporate & Other, ELV recorded a $935 million accrual in H1 2026 as a best estimate of potential exposure related to a CMS notice on historical Medicare Advantage risk adjustment data. In May 2026, ELV settled the dispute by refunding the government $342 million, successfully avoiding CMS sanctions and enrollment pauses.
Elevance's Q2 2026 performance perfectly illustrates the core thesis of The Managed Care Profit Engine: Vertical Integration, Services, and the Regulated Margin Myth: Carelon represents the high-margin, stable profit engine that shields the enterprise when government-sponsored insurance programs face severe cyclical headwinds.
Verbatim Quotes
"We expect to exit additional Medicaid markets over the next 12 to 18 months, where we do not see a path to sustainable performance.1 These are targeted portfolio actions, and they do not change our commitment to serving Medicaid members in markets where we can deliver value for states, members, and shareholders." — Gail K. Boudreaux, Elevance Health President and CEO, Q2 2026 Earnings Call Insurancenewsnet ELV Q2 Summary
"Despite mid-year rate increases in some states, executives are still forecasting that Elevance’s Medicaid operating margin in 2026 will be negative 1.75%." — Healthcare Innovation Analysis Elevance Preparing to Exit Several Medicaid States
-
An instance of Private underwriting of government healthcare collapses the moment federal rate freezes collide with rising utilization. — It demonstrates a major insurer executing strategic exits from government-subsidized markets when flat federal reimbursement fails to keep pace with member acuity. ↩︎